Total Payments
$320,001
2024 Payments
$91,480
Companies
25
Transactions
196
Medicare Patients
141
Medicare Billing
$38,110
Payment Breakdown by Category
Consulting$214,847 (67.1%)
Travel$40,833 (12.8%)
Other$30,438 (9.5%)
Research$29,376 (9.2%)
Food & Beverage$4,507 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $214,847 | 37 | 67.1% |
| Travel and Lodging | $40,833 | 32 | 12.8% |
| Unspecified | $29,376 | 40 | 9.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,038 | 28 | 7.8% |
| Honoraria | $5,400 | 2 | 1.7% |
| Food and Beverage | $4,507 | 57 | 1.4% |
Payments by Type
General
$290,626
156 transactions
Research
$29,376
40 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $72,529 | 21 | $0 (2024) |
| Chugai Pharmaceutical Co., Ltd. | $69,752 | 7 | $0 (2024) |
| F. Hoffmann-La Roche AG | $60,636 | 70 | $0 (2024) |
| Celgene Corporation | $22,011 | 12 | $0 (2022) |
| MorphoSys AG | $17,390 | 6 | $0 (2023) |
| BeiGene Switzerland GmbH | $13,805 | 3 | $0 (2023) |
| Gilead Sciences, Inc. | $12,022 | 12 | $0 (2018) |
| BeiGene USA, Inc. | $11,427 | 3 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $7,508 | 11 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $7,385 | 7 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $91,480 | 31 | Chugai Pharmaceutical Co., Ltd. ($69,752) |
| 2023 | $86,070 | 32 | Genentech, Inc. ($54,804) |
| 2022 | $22,139 | 15 | BeiGene USA, Inc. ($5,220) |
| 2021 | $17,828 | 9 | MorphoSys AG ($6,160) |
| 2020 | $11,271 | 15 | F. Hoffmann-La Roche AG ($6,346) |
| 2019 | $6,732 | 10 | F. Hoffmann-La Roche AG ($3,825) |
| 2018 | $57,374 | 44 | F. Hoffmann-La Roche AG ($23,753) |
| 2017 | $27,107 | 40 | Celgene Corporation ($9,979) |
All Payment Transactions
196 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,763.08 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,368.36 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $880.83 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $755.00 | Research |
| Study: Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $652.34 | Research |
| Study: Polarix | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $284.44 | Research |
| Study: Polarix | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $158.67 | Research |
| Study: LEO DLBCL R R | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $59.88 | Research |
| Study: Polarix | ||||||
| 09/06/2024 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $26.18 | General |
| 09/01/2024 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $3,420.00 | General |
| 09/01/2024 | Chugai Pharmaceutical Co., Ltd. | — | Travel and Lodging | Cash or cash equivalent | $574.54 | General |
| 09/01/2024 | Chugai Pharmaceutical Co., Ltd. | — | Food and Beverage | In-kind items and services | $157.57 | General |
| 08/31/2024 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $56,367.00 | General |
| 08/31/2024 | Chugai Pharmaceutical Co., Ltd. | — | Travel and Lodging | Cash or cash equivalent | $8,356.24 | General |
| 08/31/2024 | Chugai Pharmaceutical Co., Ltd. | — | Travel and Lodging | Cash or cash equivalent | $574.57 | General |
| 08/31/2024 | Chugai Pharmaceutical Co., Ltd. | — | Food and Beverage | In-kind items and services | $302.02 | General |
| 08/09/2024 | Stryker Corporation | VARIAX (Device) | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: TRAUMA & EXTREMETIES | ||||||
| 07/16/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $59.12 | General |
| Category: BioOncology | ||||||
| 07/15/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $62.01 | General |
| Category: BioOncology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $3,026.02 | Research |
| Study: Obinutuzumab Gazyva Polatuzumab Vedotin Venetoclax GDC 0199 in RR FL DLBCL | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $820.51 | Research |
| Study: Moving beyond cell of origin subtypes in POLARIX towards molecular profiling of DLBCL for precision medicine | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $468.02 | Research |
| Study: Polarix | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $85.39 | Research |
| Study: Polarix | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $60.04 | Research |
| Study: Polarix | ||||||
| 06/13/2024 | Genentech, Inc. | Columvi (Biological) | Consulting Fee | Cash or cash equivalent | $870.00 | General |
| Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Polarix | F. Hoffmann-La Roche AG | $8,097 | 19 |
| Ph 3 study of glofitamab with GemOx vs rituximab with GemOx in patients with R R DLBCL | F. Hoffmann-La Roche AG | $6,767 | 4 |
| CC-5013-CLL-010 | Celgene Corporation | $4,267 | 1 |
| Obinutuzumab Gazyva Polatuzumab Vedotin Venetoclax GDC 0199 in RR FL DLBCL | F. Hoffmann-La Roche AG | $3,909 | 3 |
| Celgene - Connect CLL | Celgene Corporation | $2,533 | 1 |
| A PHASE IbII STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND RITUXIMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA | F. Hoffmann-La Roche AG | $1,265 | 4 |
| R Benda CD79b | F. Hoffmann-La Roche AG | $1,084 | 3 |
| Moving beyond cell of origin subtypes in POLARIX towards molecular profiling of DLBCL for precision medicine | F. Hoffmann-La Roche AG | $820.51 | 1 |
| A PHASE IBII STUDY EVALUATING THE SAFETY, TOLERABILITY AND ANTI-TUMOR ACTIVITY OF POLATUZUMAB VEDOTIN DCDS4501A IN COMBINATION WITH RITUXIMAB R OR OBINUTUZUMAB G PLUS BENDAMUSTINE B IN RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA | F. Hoffmann-La Roche AG | $474.08 | 3 |
| LEO DLBCL R R | F. Hoffmann-La Roche AG | $158.67 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 24 | 109 | $31,437 | $10,484 |
| 2022 | 3 | 90 | 210 | $68,511 | $20,125 |
| 2021 | 2 | 27 | 77 | $24,719 | $7,501 |
Total Patients
141
Total Services
396
Medicare Billing
$38,110
Procedure Codes
6
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 109 | $31,437 | $10,484 | 33.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 43 | 156 | $44,148 | $13,042 | 29.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 28 | 32 | $17,660 | $5,175 | 29.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 19 | 22 | $6,703 | $1,909 | 28.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 65 | $18,395 | $5,517 | 30.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 12 | $6,324 | $1,984 | 31.4% |
About Dr. Christopher Flowers, M.D
Dr. Christopher Flowers, M.D is a Hematology & Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174630503.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Flowers, M.D has received a total of $320,001 in payments from pharmaceutical and medical device companies, with $91,480 received in 2024. These payments were reported across 196 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($214,847).
As a Medicare-enrolled provider, Flowers has provided services to 141 Medicare beneficiaries, totaling 396 services with total Medicare billing of $38,110. Data is available for 3 years (2021–2023), covering 6 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Houston, TX
- Active Since 08/23/2006
- Last Updated 09/25/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1174630503
Products in Payments
- Polivy (Biological) $30,009
- GAZYVA (Biological) $19,484
- BRUKINSA (Drug) $19,142
- Non-Covered Product (Drug) $14,919
- Zydelig (Drug) $12,022
- MONJUVI (Drug) $10,780
- Revlimid (Drug) $9,401
- Non-Covered $7,508
- CALQUENCE (Drug) $7,385
- POLIVY (Biological) $7,336
- ADCETRIS (Biological) $5,985
- Columvi (Biological) $4,386
- Zevalin (Drug) $4,248
- TAZVERIK (Drug) $2,900
- Lunsumio (Biological) $2,850
- IMBRUVICA (Drug) $2,408
- TRINAV INFUSION SYSTEM (Device) $154.19
- VENCLEXTA (Drug) $116.07
- Yescarta (Drug) $103.36
- GAMMA (Device) $44.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Houston
Devesh Pandya, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
Elias Jabbour, M.d, M.D
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Naval Daver, Mbbs, MBBS
Hematology & Oncology — Payments: $983,097
Hematology & Oncology $983,097
Jorge Cortes-Franco, M.d, M.D
Hematology & Oncology — Payments: $927,016
Hematology & Oncology $927,016
Dr. Luis Camacho, M.d., Mph, M.D., MPH
Hematology & Oncology — Payments: $491,819
Hematology & Oncology $491,819
Luhua Wang, M.d, M.D
Hematology & Oncology — Payments: $310,452
Hematology & Oncology $310,452